Pharma BD Deal Intelligence
Sarepta's $1.075B licensing deal for Arrowhead's RNAi rare-disease pipeline is holding up as a genuine platform bet: despite Sarepta's mid-2025 restructuring, the collaboration survived intact, ARO-DM1 hit two enrollment milestones, and March 2026 Phase 1/2 data showed dose-dependent exposure and favorable tolerability for both lead candidates.
Sarepta and Arrowhead partner to advance RNA-based drugs in rare diseases with $825M upfront and up to $10B in milestones
Arrowhead earns $100M milestone on first ARO-DM1 Phase 1/2 enrollment target.
First Ph1/2 data for SRP-1001 (FSHD1) and SRP-1003 (DM1): dose-dependent muscle exposure, early biomarker effects, favorable tolerability.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
In November 2024 Sarepta Therapeutics entered a global license and collaboration agreement for Arrowhead Pharmaceuticals' clinical and preclinical siRNA/RNAi programs in rare genetic diseases (including FSHD1, myotonic dystrophy type 1, IPF and CNS indications). The deal closed February 10, 2025, with Arrowhead receiving $500M upfront, a $325M equity investment (stock purchased at $27.25/share) and $250M in installment payments ($50M/yr over five years), plus contingent milestones. The agreement weathered Sarepta's mid-2025 corporate restructuring: on July 23, 2025 Arrowhead confirmed the collaboration remained in effect and that Sarepta had prioritized the licensed RNAi programs as central to its future. Arrowhead subsequently earned two ARO-DM1 enrollment milestones -- $100M (July 28, 2025) and $200M (November 24, 2025). On March 25, 2026 Sarepta reported the first Phase 1/2 clinical data for SRP-1001 (ARO-DUX4, FSHD1) and SRP-1003 (ARO-DM1, DM1), showing dose-dependent muscle exposure, early biomarker effects and favorable tolerability.
16K US cases/yr · $1.0B Projected FSHD Rx Market
FSHD is one of the most common muscular dystrophies, caused by aberrant expression of the DUX4 protein in skeletal muscle. No approved therapy exists. ARO-DUX4 uses RNA interference to silence DUX4 expression, addressing the root molecular cause.
ARO-DUX4 is the most advanced DUX4-targeting therapy in development. Phase 1/2 trial is ongoing. Competitors include Avidity Biosciences (AOC 1001 for DM1, different indication) and Dyne Therapeutics muscle-targeting approaches.
Sarepta licensed RNAi candidates for rare neuromuscular and pulmonary conditions.
Arrowhead confirmed the Sarepta collaboration remains in effect; Sarepta's 2025 restructuring prioritized the licensed RNAi programs as central to its future.
First of two prespecified Phase 1/2 ARO-DM1 enrollment targets reached with authorization to dose-escalate, triggering a $100M milestone payment from Sarepta.
Second ARO-DM1 enrollment milestone reached after DSMB review and dose-escalation authorization, triggering a $200M payment from Sarepta (due within 60 days).
Sarepta reported first clinical data for SRP-1001 (ARO-DUX4, FSHD1) and SRP-1003 (ARO-DM1, DM1): dose-dependent muscle exposure, early biomarker effects and favorable tolerability after single dose.
Deal closed Feb 2025 and survived Sarepta's 2025 restructuring as a prioritized program. $300M ARO-DM1 milestones earned (2025); first Ph1/2 data (Mar 2026) showed dose-dependent muscle exposure and favorable tolerability.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sarepta Therapeutics Inc. / Arrowhead Pharmaceuticals Inc. (this deal) | 2024 | $1.1B | 72 |
| Sarepta Therapeutics Inc. / StrideBio, Inc | 2019 | — | — |
| Sarepta Therapeutics Inc. / Genevant Sciences | 2021 | — | — |
| Sarepta Therapeutics Inc. / Myonexus Therapeutics | 2019 | — | — |
| Sarepta Therapeutics Inc. / Codiak BioSciences, Inc. | 2020 | — | — |
| Sarepta Therapeutics Inc. / GenEdit, Inc. | 2022 | — | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
← Browse all deals · How we score deals
More: 2024 deals · Sarepta Therapeutics Inc. deals · Neurology deals